ROCK as a therapeutic target for ischemic stroke

References

• Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016;133(4):e38-360.
   Google Scholar
• Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke. 1994 Sep;25(9):1721–1725.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017 Mar 07;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• del Zoppo GJ. The neurovascular unit in the setting of stroke. J Intern Med. 2010 Feb;267(2):156–171.
   PubMed Web of Science ®Google Scholar
• Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996 Aug 26;392(2):189–193.
   PubMed Web of Science ®Google Scholar
• Leung T, Manser E, Tan L, et al. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995 Dec 8;270(49):29051–29054.
   PubMed Web of Science ®Google Scholar
• Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996 May 1;15(9):2208–2216.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Sasaki T, Mammoto A, et al. Interaction of radixin with Rho small G protein GDP/GTP exchange protein Dbl. Oncogene. 1998 Jun 25;16(25):3279–3284.
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996 Apr 15;15(8):1885–1893.
   PubMed Web of Science ®Google Scholar
• Leung T, Chen XQ, Manser E, et al. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol. 1996 Oct;16(10):5313–5327.
   PubMed Web of Science ®Google Scholar
• Amano M, Chihara K, Nakamura N, et al. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem. 1999 Nov 5;274(45):32418–32424.
   PubMed Web of Science ®Google Scholar
• Garg R, Riento K, Keep N, et al. N-terminus-mediated dimerization of ROCK-I is required for RhoE binding and actin reorganization. Biochem J. 2008 Apr 15;411(2):407–414.
   PubMed Web of Science ®Google Scholar
• Jacobs M, Hayakawa K, Swenson L, et al. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2006 Jan 6;281(1):260–268.
   PubMed Web of Science ®Google Scholar
• Sin WC, Chen XQ, Leung T, et al. RhoA-binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network. Mol Cell Biol. 1998 Nov;18(11):6325–6339.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Tan I, Ng CH, et al. Characterization of RhoA-binding kinase ROKalpha implication of the pleckstrin homology domain in ROKalpha function using region-specific antibodies. J Biol Chem. 2002 Apr 12;277(15):12680–12688.
   PubMed Web of Science ®Google Scholar
• Kimura K, Fukata Y, Matsuoka Y, et al. Regulation of the association of adducin with actin filaments by Rho-associated kinase (Rho-kinase) and myosin phosphatase. J Biol Chem. 1998 Mar 6;273(10):5542–5548.
   PubMed Web of Science ®Google Scholar
• Inada H, Togashi H, Nakamura Y, et al. Balance between activities of Rho kinase and type 1 protein phosphatase modulates turnover of phosphorylation and dynamics of desmin/vimentin filaments. J Biol Chem. 1999 Dec 3;274(49):34932–34939.
   PubMed Web of Science ®Google Scholar
• Pelosi M, Marampon F, Zani BM, et al. ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic program. Mol Cell Biol. 2007 Sep;27(17):6163–6176.
   PubMed Web of Science ®Google Scholar
• Smith AL, Dohn MR, Brown MV, et al. Association of Rho-associated protein kinase 1 with E-cadherin complexes is mediated by p120-catenin. Mol Biol Cell. 2012 Jan;23(1):99–110.
   PubMed Web of Science ®Google Scholar
• Chevrier V, Piel M, Collomb N, et al. The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol. 2002 May 27;157(5):807–817. 12034773.
   PubMed Web of Science ®Google Scholar
• Farber MJ, Rizaldy R, Hildebrand JD. Shroom2 regulates contractility to control endothelial morphogenesis. Mol Biol Cell. 2011 Mar 15;22(6):795–805.
   PubMed Web of Science ®Google Scholar
• Boureux A, Vignal E, Faure S, et al. Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol. 2007 Jan;24(1):203–216.
   PubMed Web of Science ®Google Scholar
• Coleman ML, Sahai EA, Yeo M, et al. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001 Apr;3(4):339–345.
   PubMed Web of Science ®Google Scholar
• Sebbagh M, Renvoize C, Hamelin J, et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001 Apr;3(4):346–352.
   PubMed Web of Science ®Google Scholar
• Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken, NJ). 2010 Sep;67(9):545–554.
   PubMed Web of Science ®Google Scholar
• Schofield AV, Bernard O. Rho-associated coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem Mol Biol. 2013 Jul-Aug;48(4):301–316.
   PubMed Web of Science ®Google Scholar
• Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846.
   PubMedGoogle Scholar
• Kang JH, Jiang Y, Toita R, et al. Phosphorylation of Rho-associated kinase (Rho-kinase/ROCK/ROK) substrates by protein kinases A and C. Biochimie. 2007 Jan;89(1):39–47.
   PubMed Web of Science ®Google Scholar
• Riou P, Kjaer S, Garg R, et al. 14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins. Cell. 2013 Apr 25;153(3):640–653.
   PubMed Web of Science ®Google Scholar
• Thumkeo D, Watanabe S, Narumiya S. Physiological roles of Rho and Rho effectors in mammals. Eur J Cell Biol. 2013 Oct-Nov;92(10–11):303–315.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67(1):103–117.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Nishimura D, Wu RC, et al. Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase. J Biol Chem. 2006 Jun 2;281(22):15320–15329.
   PubMed Web of Science ®Google Scholar
• Koch JC, Tonges L, Barski E, et al. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis. 2014;5:e1225.
   PubMed Web of Science ®Google Scholar
• Forgione N, Fehlings MG. Rho-ROCK inhibition in the treatment of spinal cord injury. World Neurosurg. 2014 Sep-Oct;82(3–4):e535–e539.
   PubMed Web of Science ®Google Scholar
• Fournier AE, Takizawa BT, Strittmatter SM. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neuroscience. 2003 Feb 15;23(4):1416–1423.
   PubMed Web of Science ®Google Scholar
• Boato F, Hendrix S, Huelsenbeck SC, et al. C3 peptide enhances recovery from spinal cord injury by improved regenerative growth of descending fiber tracts. J Cell Sci. 2010 May 15;123(Pt 10):1652–1662.
   PubMed Web of Science ®Google Scholar
• Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005 Oct;36(10):2251–2257.
   PubMed Web of Science ®Google Scholar
• Wang QM, Stalker TJ, Gong Y, et al. Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. Vasc Med. 2012 Dec;17(6):379–385.
   PubMed Web of Science ®Google Scholar
• Hyun LJ, Zheng Y, von Bornstadt D, et al. Selective ROCK2 inhibition in focal cerebral ischemia. Ann Clin Translational Neurol. 2014 Jan;1(1):2–14.
   PubMed Web of Science ®Google Scholar
• Shibuya M, Hirai S, Seto M, et al. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005 Nov 15;238(1–2):31–39. PubMed PMID: 16005902.
   PubMed Web of Science ®Google Scholar
• Feske SK, Sorond FA, Henderson GV, et al. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res. 2009 Feb 27;1257:89–93.
   PubMed Web of Science ®Google Scholar
• Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008 Nov 1;112(9):3555–3562.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Shin JW, Wang Y, et al. RhoA is essential for maintaining normal megakaryocyte ploidy and platelet generation [Research Support, N.I.H., Extramural]. PloS One. 2013;8(7):e69315.
   PubMed Web of Science ®Google Scholar
• Pleines I, Hagedorn I, Gupta S, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood. 2012 Jan 26;119(4):1054–1063.
   PubMed Web of Science ®Google Scholar
• Klages B, Brandt U, Simon MI, et al. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol. 1999 Feb 22;144(4):745–754.
   PubMed Web of Science ®Google Scholar
• Sladojevic N, Oh GT, Kim HH, et al. Decreased thromboembolic stroke but not atherosclerosis or vascular remodeling in mice with ROCK2-deficient platelets. Cardiovasc Res. 2017 Apr 14.
   PubMed Web of Science ®Google Scholar
• Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Curr Opin Neurol. 2012 Jun;25(3):334–340.
   PubMed Web of Science ®Google Scholar
• Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998 Sep 11;273(37):24266–24271.
   PubMed Web of Science ®Google Scholar
• Satoh S, Kobayashi T, Hitomi A, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol. 1999 May;80(1):41–48.
   PubMedGoogle Scholar
• Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001 Aug 10;69(12):1441–1453.
   PubMed Web of Science ®Google Scholar
• Hara M, Takayasu M, Watanabe K, et al. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J Neurosurg. 2000 Jul;93(1 Suppl):94–101.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fan Y, Won SJ, et al. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke. 2007 Jan;38(1):146–152.
   PubMed Web of Science ®Google Scholar
• Brecht S, Schwarze K, Waetzig V, et al. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain. Neuroscience. 2003;120(4):1037–1048.
   PubMed Web of Science ®Google Scholar
• Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011 Jan;69(1):119–129.
   PubMed Web of Science ®Google Scholar
• Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7446–7451.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Oukka M, Torgerson TR. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol. 2009 May;123(5):977-983; quiz 984-985.
   Web of Science ®Google Scholar
• Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010 May;87(5):779–789.
   PubMed Web of Science ®Google Scholar
• Kim ES, Kim RS, Ren RF, et al. Transforming growth factor-beta inhibits apoptosis induced by beta-amyloid peptide fragment 25-35 in cultured neuronal cells. Brain Res Mol Brain Res. 1998 Nov 20;62(2):122–130.
   PubMedGoogle Scholar
• Nakagawa M, Higuchi I, Yoshidome H, et al. Familial facioscapulohumeral muscular dystrophy: phenotypic diversity and genetic abnormality. Acta Neurol Scand. 1996 Feb-Mar;93(2–3):189–192.
   PubMed Web of Science ®Google Scholar
• Shimada H, Rajagopalan LE. Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65. J Biol Chem. 2010 Apr 23;285(17):12536–12542.
   PubMed Web of Science ®Google Scholar
• Caplan S, Zeliger S, Wang L, et al. Cell-surface-expressed T-cell antigen-receptor zeta chain is associated with the cytoskeleton. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4768–4772.
   PubMed Web of Science ®Google Scholar
• Heasman SJ, Ridley AJ. Multiple roles for RhoA during T cell transendothelial migration. Small GTPases. 2010 Nov;1(3):174–179.
   PubMedGoogle Scholar
• Teramoto H, Salem P, Robbins KC, et al. Tyrosine phosphorylation of the vav proto-oncogene product links FcepsilonRI to the Rac1-JNK pathway. J Biol Chem. 1997 Apr 18;272(16):10751–10755.
   PubMed Web of Science ®Google Scholar
• Perona R, Montaner S, Saniger L, et al. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997 Feb 15;11(4):463–475.
   PubMed Web of Science ®Google Scholar
• Biswas PS, Gupta S, Chang E, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest. 2010 Sep;120(9):3280–3295.
   PubMed Web of Science ®Google Scholar
• Allan LM, Rowan EN, Firbank MJ, et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain. 2011 Dec;134(Pt 12):3716–3727.
   PubMed Web of Science ®Google Scholar
• Doyle KP, Quach LN, Sole M. B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci. 2015 Feb 4;35(5):2133–2145.
   PubMed Web of Science ®Google Scholar
• Natkanski E, Lee WY, Mistry B, et al. B cells use mechanical energy to discriminate antigen affinities. Science (New York, NY). 2013 Jun 28;340(6140):1587–1590.
   Google Scholar
• McDonald DA, Shi C, Shenkar R, et al. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke. 2012 Feb;43(2):571–574.
   PubMed Web of Science ®Google Scholar
• Ding J, Li QY, Wang X, et al. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice. J Neurochem. 2010 Sep;114(6):1619–1629.
   PubMed Web of Science ®Google Scholar
• Wang HW, Liu PY, Oyama N, et al. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J. 2008 Oct;22(10):3561–3570.
   PubMed Web of Science ®Google Scholar
• Matoba K, Kawanami D, Ishizawa S, et al. Rho-kinase mediates TNF-alpha-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun. 2010 Nov 26;402(4):725–730.
   PubMed Web of Science ®Google Scholar
• Zandi S, Nakao S, Chun KH, et al. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Rep. 2015 Feb 24;10(7):1173–1186.
   PubMed Web of Science ®Google Scholar
• Barakat R, Redzic Z. The role of activated microglia and resident macrophages in the neurovascular unit during cerebral ischemia: is the jury still out? Med Princ Pract. 2015 Aug 19;25:3–14.
   PubMed Web of Science ®Google Scholar
• Isgro J, Gupta S, Jacek E, et al. Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum. 2013 Jun;65(6):1592–1602.
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814–16819.
   PubMed Web of Science ®Google Scholar
• Lally L, Pernis A, Narula N, et al. Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. Rheumatology (Oxford, England). 2015 Mar;54(3):554–558.
   PubMed Web of Science ®Google Scholar
• Stamatovic SM, Keep RF, Kunkel SL, et al. Potential role of MCP-1 in endothelial cell tight junction ‘opening’: signaling via Rho and Rho kinase. J Cell Sci. 2003 Nov 15;116(Pt 22):4615–4628.
   PubMed Web of Science ®Google Scholar
• He QW, Xia YP, Chen SC, et al. Astrocyte-derived sonic hedgehog contributes to angiogenesis in brain microvascular endothelial cells via RhoA/ROCK pathway after oxygen-glucose deprivation. Mol Neurobiol. 2013 Jun;47(3):976–987.
   PubMed Web of Science ®Google Scholar
• Tonges L, Koch JC, Bahr M, et al. ROCKing regeneration: rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci. 2011;4:39.
   PubMed Web of Science ®Google Scholar
• Tonges L, Frank T, Tatenhorst L, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease. Brain. 2012 Nov;135(Pt 11):3355–3370.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Kotani Y, Nakajima Y, et al. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res. 2007 Jun;18(1154):215–224.
   Web of Science ®Google Scholar
• Ding J, Yu JZ, Li QY, et al. Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav Immun. 2009 Nov;23(8):1083–1088.
   PubMed Web of Science ®Google Scholar
• Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1767–1775.
   PubMed Web of Science ®Google Scholar
• Lohn M, Plettenburg O, Ivashchenko Y, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension. 2009 Sep;54(3):676–683.
   PubMed Web of Science ®Google Scholar
• Williams RD, Novack GD, van Haarlem T, et al. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834–841.e1.
   PubMed Web of Science ®Google Scholar
• Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667–677.
   PubMedGoogle Scholar
• O’Brien EC, Greiner MA, Xian Y, et al. Clinical effectiveness of statin therapy after ischemic stroke: primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. Circulation. 2015 Oct 13;132(15):1404–1413.
   PubMed Web of Science ®Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017 Jan 06;120(1):229–243.
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998 May;138(1):11–24.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998. Atheroscler Suppl. 2004 Oct;5(3):99–106.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009.
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 Nov 5;339(19):1349–1357.
   Google Scholar
• West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998 Apr 21;97(15):1440–1445.
   Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64(Suppl 2):43–60.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004 May;3(5):271–278.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (Clinical Research Ed). 2003 Jun 28;326(7404):1423.
   PubMed Web of Science ®Google Scholar
• Russell RG. Bisphosphonates: the first 40 years. Bone. 2011 Jul;49(1):2–19.
   PubMed Web of Science ®Google Scholar
• Hata T, Soga J, Hidaka T, et al. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens. 2011 Feb;29(2):373–379.
   PubMed Web of Science ®Google Scholar
• Zee RYL, Wang QM, Chasman DI, et al. Gene variations of ROCKs and risk of ischaemic stroke: the Women’s Genome Health Study. Clin Sci. 2014 Jun;126(12):829–835.
   PubMed Web of Science ®Google Scholar